Security
Drugs Made In America Acquisition Corp. Ordinary Shares · DMAA
DMAANASDAQCommon stockCurrentCIK 2028614Updated Oct 22, 2026
DMAA price & chart
Loading TradingView…
NASDAQ:DMAA on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
425 filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
425 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-Q filing
Show 5 more recent filings
SCHEDULE 13G/A - filed by First Trust Capital Management L.P. regarding Drugs Made In America Acquisition Corp.
SCHEDULE 13G/A - filed by MIZUHO FINANCIAL GROUP INC regarding Drugs Made In America Acquisition Corp.
425 filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
SCHEDULE 13G - filed by Feis Equities LLC regarding Drugs Made In America Acquisition Corp.
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| AssetsUSD | 237,632,428Source | — | 146,903,435Source | 235,205,692Source | — | 242,035,303Source | 232,806,487Source | 239,918,847Source | 550,824Source |
| Current assets: | |||||||||
| Assets, CurrentUSD | 28,196Source | — | 69,184Source | 49,726Source | — | 14,887Source | 71,019Source | 12,191Source | 4,991Source |
| Prepaid Expense and Other Assets, CurrentUSD | 27,479Source | — | 48,904Source | 48,904Source | — | — | 70,096Source | 6,054Source | 3,640Source |
| LIABILITIES AND EQUITY | |||||||||
| LiabilitiesUSD | 7,356,611Source | — | 9,136,624Source | 7,201,441Source | — | 7,392,169Source | 7,247,369Source | 7,276,172Source | 795,669Source |
| Stockholders’ equity: | |||||||||
| Common Stock, Value, IssuedUSD | 1,052Source | — | 1,072Source | 1,052Source | — | 1,072Source | 1,052Source | 1,072Source | 986Source |
| Additional Paid in CapitalUSD | — | — | — | — | — | — | — | — | 34,014Source |
| Retained Earnings (Accumulated Deficit)USD | -6,720,645Source | — | -7,407,288Source | -6,456,942Source | — | -7,378,354Source | -6,325,023Source | -7,265,053Source | -279,845Source |
| Stockholders' Equity Attributable to ParentUSD | -7,328,415Source | -164,859Source | -7,406,216Source | -7,151,715Source | -19,931Source | -7,377,282Source | -7,176,350Source | -7,263,981Source | -244,845Source |
| Liabilities and EquityUSD | 237,632,428Source | — | 146,903,435Source | 235,205,692Source | — | 242,035,303Source | 232,806,487Source | 239,918,847Source | 550,824Source |
| Current liabilities: | |||||||||
| Liabilities, CurrentUSD | 456,611Source | — | 2,944,624Source | 301,441Source | — | 492,169Source | 347,369Source | 376,172Source | — |
| Additional Financial Items | |||||||||
| Accrued Liabilities, CurrentUSD | 302,623Source | — | — | 147,453Source | — | — | 132,483Source | — | 77,280Source |
| Cash and Cash Equivalents, at Carrying Value | — | — | —Source | — | — | —Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -91,250Source | -251,244Source | -539,187Source | — |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -231,150,000Source | -231,150,000Source | — |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 100,000Source | 231,400,816Source | 231,693,973Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 717Source | 2,095Source | 20,280Source | 822Source | 18,098Source | 14,887Source | 923Source | 6,137Source | 1,351Source |
| Additional Financial Items | ||||||||||
| General and Administrative ExpenseUSD | — | 263,703Source | 144,928Source | 136,934Source | 131,919Source | — | 143,301Source | 330,925Source | 2,816,013Source | — |
| Investment Income, InterestUSD | — | 2,448,266Source | — | 1,863,831Source | 2,420,498Source | — | 2,113,760Source | 1,585,468Source | 8,756,656Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | 2,184,563Source | -144,928Source | 1,726,897Source | 2,288,579Source | — | 1,970,459Source | 1,254,543Source | 5,940,643Source | — |
| Nonoperating Income (Expense)USD | — | 2,448,266Source | — | 1,863,831Source | 2,420,498Source | — | 2,113,760Source | 1,585,468Source | 8,756,656Source | — |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | 94,574Source | 141,976Source | — |
| Proceeds from Contributions from AffiliatesUSD | — | — | — | — | — | — | — | — | 1,345,844Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | -263,703Source | -144,928Source | -136,934Source | -131,919Source | -143,301Source | -330,925Source | -2,816,013Source |
| Net Income (Loss) Attributable to ParentUSD | — | 2,184,563Source | -144,928Source | 1,726,897Source | 2,288,579Source | 1,970,459Source | 1,254,543Source | 5,940,643Source |
| Additional Financial Items | ||||||||
| General and Administrative ExpenseUSD | — | 263,703Source | 144,928Source | 136,934Source | 131,919Source | 143,301Source | 330,925Source | 2,816,013Source |
| Investment Income, InterestUSD | — | 2,448,266Source | — | 1,863,831Source | 2,420,498Source | 2,113,760Source | 1,585,468Source | 8,756,656Source |
| Nonoperating Income (Expense)USD | — | 2,448,266Source | — | 1,863,831Source | 2,420,498Source | 2,113,760Source | 1,585,468Source | 8,756,656Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | 94,574Source | 141,976Source |
Offerings
Registration 333-281170
- Gross proceeds
- 200000000.0
- Net proceeds
- 193000000.0
- Deal price
- 10.0
- Shares
- 20000000
- Offering amount
- $200,000,000
- Offering price
- $10.00
- Ticker
- DMAAU
Filing attachments
ea028566201ex4-5.htm · 10-K · 2026-04-15
Exhibit 4.5 DRUGS MADE IN AMERICA ACQUISITION CORP. DESCRIPTION OF SECURITIES The following summary of the material terms of the securities of Drugs Made In America Acquisition Corp. (“we,” “us,” “our” or “the Company”) is not intended to be a complete summary of the rights and preferences of such securities and is subject to and qualified by reference to our amended and restated memorandum and articles of association incorporated by reference as an exhibit to the Company’s Annual Report on F…
Read attachment ↗